Autopsy report · NCT00334685

[S,S]-Reboxetine Add-On Trial

“The Data Monitoring Committee terminated the study on the basis of futility (insufficient clinical response).”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 136 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Pain

Interventions

[S,S]-Reboxetine + Pregabalin; Pregabalin

Participants

136

Sites

83

Countries

Austria, Canada, Czechia, Germany, Italy, Latvia, Netherlands, Norway, Poland, Russia, Spain, Sweden and more

Trials that died the same way

• Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults
  “This study was terminated early due to futility.” (78% match in meaning)
• Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)
  “This trial was terminated following a futility analysis confirming futility of continuing the study” (76% match in meaning)
• Trial to Evaluate UltraSound in the Treatment of Tibial Fractures
  “Study was terminated due to futility” (75% match in meaning)
• CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
  “Study was terminated after the planned interim analysis as the pre-defined futility threshold was met” (74% match in meaning)
• Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
  “The study was terminated due to futility and lack of future funding” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.